title: Subthalamic nucleus stimulation increases brain derived neurotrophic factor in the nigrostriatal system and primary motor cortex.
abstract: The mechanisms underlying the effects of long-term deep brain stimulation of the subthalamic nucleus (STN DBS) as a therapy for Parkinson's disease (PD) remain poorly understood. The present study examined whether functionally effective, long-term STN DBS modulates glial cell line-derived neurotrophic factor (GDNF) and/or brain-derived neurotrophic factor (BDNF) in both unlesioned and unilateral 6-hydroxydopamine lesioned rats. Lesioned rats that received two weeks of continuous unilateral STN DBS exhibited significant improvements in parkinsonian motor behaviors in tests of forelimb akinesia and rearing activity. Unilateral STN DBS did not increase GDNF in the nigrostriatal system, primary motor cortex (M1), or hippocampus of unlesioned rats. In contrast, unilateral STN DBS increased BDNF protein 2-3 fold bilaterally in the nigrostriatal system with the location (substantia nigra vs. striatum) dependent upon lesion status. Further, BDNF protein was bilaterally increased in M1 cortex by as much as 2 fold regardless of lesion status. STN DBS did not impact cortical regions that receive less input from the STN. STN DBS also was associated with bilateral increases in BDNF mRNA in the substantia nigra (SN) and internal globus pallidus (GPi). The increase observed in GPi was completely blocked by pretreatment with 5-Methyl-10,11-dihydro-5 H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), suggesting that the activation of N-methyl-D-aspartate (NMDA) receptors was involved in this phenomenon. The upregulation of BDNF associated with long term STN DBS suggest that this therapy may exert pronounced and underappreciated effects on plasticity in the basal ganglia circuitry that may play a role in the symptomatic effects of this therapy as well as support the neuroprotective effect of stimulation documented in this rat model.
authors.affiliation: Department of Neurology, University of Cincinnati, OH, USA.
authors.forename: Anne L
authors.initials: AL
authors.lastname: Spieles-Engemann
authors.forename: Kathy
authors.initials: K
authors.lastname: Steece-Collier
authors.forename: Michael M
authors.initials: MM
authors.lastname: Behbehani
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: Collier
authors.forename: Susan L
authors.initials: SL
authors.lastname: Wohlgenant
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Kemp
authors.forename: Allyson
authors.initials: A
authors.lastname: Cole-Strauss
authors.forename: Nathan D
authors.initials: ND
authors.lastname: Levine
authors.forename: Sara E
authors.initials: SE
authors.lastname: Gombash
authors.forename: Valerie B
authors.initials: VB
authors.lastname: Thompson
authors.forename: Jack W
authors.initials: JW
authors.lastname: Lipton
authors.forename: Caryl E
authors.initials: CE
authors.lastname: Sortwell
mesh_terms: D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics / Q000378:metabolism*; D003342:Corpus Striatum / Q000378:metabolism*; D046690:Deep Brain Stimulation; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005786:Gene Expression Regulation / Q000502:physiology; D008297:Male; D009044:Motor Cortex / Q000378:metabolism*; D009498:Neurotoxins / Q000633:toxicity; D016627:Oxidopamine / Q000633:toxicity; D010300:Parkinson Disease / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D011597:Psychomotor Performance / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013378:Substantia Nigra / Q000378:metabolism*; D020531:Subthalamic Nucleus / Q000502:physiology*
chemical_list: D019208:Brain-Derived Neurotrophic Factor; D009498:Neurotoxins; D016627:Oxidopamine